Alnylam Pharmaceuticals (ALNY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 09-2019 | 06-2019 | 03-2019 | 12-2018 | 09-2018 | |
| Sales | 70,061 | 44,714 | 33,294 | 21,033 | 2,069 |
| Cost of Goods | 5,213 | 4,326 | 3,347 | 1,665 | 137 |
| Gross Profit | 64,848 | 40,388 | 29,947 | 19,368 | 1,932 |
| Operating Expenses | 281,360 | 276,985 | 219,082 | 240,389 | 256,627 |
| Operating Income | -216,299 | -236,271 | -188,788 | -220,356 | -254,558 |
| Other Income | 7,370 | 17,750 | 7,568 | 9,276 | 9,721 |
| Pre-tax Income | -208,929 | -218,521 | -181,220 | -211,080 | -244,837 |
| Income Tax | -394 | 960 | 695 | 361 | 445 |
| Net Income Continuous | -208,535 | -219,481 | -181,915 | -211,441 | -245,282 |
| Net Income | $-208,535 | $-219,481 | $-181,915 | $-211,441 | $-245,282 |
| EPS Basic Total Ops | -1.92 | -2.02 | -1.73 | -2.10 | -2.43 |
| EPS Basic Continuous Ops | -1.92 | -2.02 | -1.73 | -2.10 | -2.43 |
| EPS Diluted Total Ops | -1.92 | -2.02 | -1.73 | -2.10 | -2.43 |
| EPS Diluted Continuous Ops | -1.92 | -2.02 | -1.73 | -2.10 | -2.43 |
| EBITDA(a) | $-202,971 | $-224,086 | $-174,695 | $-210,930 | $-254,153 |